Cullinan Therapeutics Inc. (CGEM) Statistics & Valuation Metrics - Stocknear

Cullinan Therapeutics Inc...

NASDAQ: CGEM · Real-Time Price · USD
5.96
-0.03 (-0.50%)
At close: Sep 26, 2025, 3:59 PM
6.07
1.85%
After-hours: Sep 26, 2025, 06:23 PM EDT

Cullinan Therapeutics Statistics

Share Statistics

Cullinan Therapeutics has 59.07M shares outstanding. The number of shares has increased by 1.79% in one year.

59.07M
1.79%
0.86%
99.99%
36.05M
2,000
0.44%

Short Selling Information

The latest short interest is 6.18M, so 10.46% of the outstanding shares have been sold short.

6.18M
10.46%
12.1%
8.39

Valuation Ratios

The PE ratio is -3.91 and the forward PE ratio is -1.67. Cullinan Therapeutics's PEG ratio is 0.25.

-3.91
-1.67
0
13.6
1.11
-4.51
0.25
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Cullinan Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 13.53, with a Debt / Equity ratio of 0.

13.53
13.53
0
-0.01
-0.01
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-1.51M
111
0
n/a

Taxes

117K
-0.07%

Stock Price Statistics

The stock price has increased by -65.33% in the last 52 weeks. The beta is -0.07, so Cullinan Therapeutics's price volatility has been lower than the market average.

-0.07
-65.33%
7.29
8.61
34.5
450,915

Income Statement

n/a
-306K
-196.92M
-167.38M
-167.15M
-167.46M
-3.11
Full Income Statement

Balance Sheet

The company has 83M in cash and 2.15M in debt, giving a net cash position of 80.85M.

83M
2.15M
80.85M
-368.24M
520.33M
247.85M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -145.3M and capital expenditures 0, giving a free cash flow of -145.3M.

-145.3M
n/a
-145.3M
-2.7
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

CGEM does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for CGEM is $24, which is 302.7% higher than the current price. The consensus rating is "Buy".

$24
302.7%
Buy
5
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

5.67
1